Moreover, a loss of morning peak ACTH (adrenocorticotropic hormone) and decreased responsiveness to pharmacological challenge are also reported in CFS cases compared to controls [130]. This evidence concerns the gene POMC and myalgic encephalomeyelitis/chronic fatigue syndrome.